.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The BOLD phase 2 study provided early dose-finding evidence for siponimod, an oral selective sphingosine-1-phosphate receptor modulator. Adults with relapsing-remitting multiple sclerosis were randomized to several siponimod doses or placebo and followed with serial MRI assessments. Siponimod produced a dose-dependent reduction in inflammatory MRI activity, helping identify the dose later used in phase 3 development. The study also established short-term tolerability and provided pharmacodynamic evidence that selective S1P modulation could meaningfully suppress disease activity. Although phase 2 MRI outcomes cannot substitute for long-term disability data, the trial was important in establishing a development pathway that ultimately led to the EXPAND trial in secondary progressive MS. For HCPs, the practical lesson is that MRI activity can be useful in early treatment evaluation, but treatment decisions should not rely on imaging alone. Clinical relapses, disability progression and safety monitoring remain central. Siponimod also requires CYP2C9 genotype-informed dosing and attention to infection, cardiac and ophthalmic risks. The study is relevant to IANCON's broad MS and disease-modifying therapy focus.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The BOLD phase 2 study provided early dose-finding evidence for siponimod, an oral selective sphingosine-1-phosphate receptor modulator. Adults with relapsing-remitting multiple sclerosis were randomized to several siponimod doses or placebo and followed with serial MRI assessments. Siponimod produced a dose-dependent reduction in inflammatory MRI activity, helping identify the dose later used in phase 3 development. The study also established short-term tolerability and provided pharmacodynamic evidence that selective S1P modulation could meaningfully suppress disease activity. Although phase 2 MRI outcomes cannot substitute for long-term disability data, the trial was important in establishing a development pathway that ultimately led to the EXPAND trial in secondary progressive MS. For HCPs, the practical lesson is that MRI activity can be useful in early treatment evaluation, but treatment decisions should not rely on imaging alone. Clinical relapses, disability progression and safety monitoring remain central. Siponimod also requires CYP2C9 genotype-informed dosing and attention to infection, cardiac and ophthalmic risks. The study is relevant to IANCON's broad MS and disease-modifying therapy focus.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
